HERTFORDSHIRE, England, and PITTSBURGH, Nov. 2, 2020 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced that Bill Szablewski, CFA, has joined the company as Head of Capital Markets, in a new leadership role working closely with senior leadership. He will be serving in that same capacity for VIATRISTM ("Viatris").
At Viatris, Szablewski will be responsible for building Viatris' brand, reputation and network of relationships in global capital markets across equity and fixed income investors. Szablewski will oversee the company's investor relations and treasury functions and will be a member the Global Finance leadership team reporting to Sanjeev Narula, the future chief financial officer of Viatris.
Mylan Executive Chairman Robert J. Coury said: "We are thrilled to welcome Bill to the team and believe that his leadership skills and vast expertise in capital markets and investor relations will be essential as we grow Viatris and develop as a company."
Szablewski added: "I'm excited to be joining Viatris at this pivotal time as we prepare to launch a new kind of healthcare company focused on delivering high-quality medicines to patients in more than 165 countries. I look forward to telling the Viatris story while building strong relationships across the investment community and financial markets globally."
Szablewski has nearly 15 years of experience in the healthcare industry. Szablewski most recently served as Assistant Treasurer, Capital Markets at Bristol Myers Squibb (NYSE: BMY). During his time at Bristol Myers Squibb, his work supported the successful shareholder vote and debt financing for the Celgene acquisition. He managed external relationships with banking counterparties, rating agencies, and fixed income investors and analysts. Prior to this role, Szablewski served as Director of Investor Relations, with responsibilities that included supporting the executive leadership team, developing and executing investor relations strategy, and global shareholder targeting campaigns. He is a CFA Charterholder, received his MBA from Drexel University and his bachelor's degree from Virginia Tech.
Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a portfolio of more than 7,500 marketed products around the world, including antiretroviral therapies on which approximately 40% of people being treated for HIV/AIDS globally depend. We market our products in more than 165 countries and territories. We are one of the world's largest producers of active pharmaceutical ingredients. Every member of our approximately 35,000-strong workforce is dedicated to creating better health for a better world, one person at a time. Learn more at Mylan.com. We routinely post information that may be important to investors on our website at investor.mylan.com.
This press release includes statements that constitute "forward-looking statements," including with regard to the proposed combination of Mylan and Pfizer's Upjohn business (the "Combination"). Because forward-looking statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such statements. Factors that could cause or contribute to such differences include, but are not limited to the completion of the Combination on the anticipated timeline or at all, and the achievement of the anticipated benefits of the Combination; the potential widespread and highly uncertain impact of public health outbreaks, epidemics and pandemics, such as the COVID-19 pandemic; any changes in, interruptions to, or difficulties with Mylan's or its partners' ability to develop, manufacture, and commercialize products; the effect of any changes in Mylan's or its partners' customer and supplier relationships and customer purchasing patterns; other changes in third-party relationships; the impact of competition; changes in the economic and financial conditions of the businesses of Mylan or its partners; the scope, timing, and outcome of any ongoing legal proceedings and the impact of any such proceedings on Mylan's or its partners' business; any regulatory, legal, or other impediments to Mylan's or its partners' ability to bring products to market; actions and decisions of healthcare and pharmaceutical regulators, and changes in healthcare and pharmaceutical laws and regulations, in the United States and abroad; Mylan's and its partners' ability to protect intellectual property and preserve intellectual property rights; risks associated with international operations; other uncertainties and matters beyond the control of management; and the other risks detailed in Mylan's filings with the Securities and Exchange Commission. Mylan undertakes no obligation to update these statements for revisions or changes after the date of this release.
SOURCE Mylan N.V.